ClinicalTrials.gg
CompletedNCT01421186Updated Nov 16, 2021Results posted

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

A Phase 1/2 interventional study of MOR03087 phase 1 dose escalation and MOR03087 in Multiple Myeloma, sponsored by MorphoSys AG. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-16.

Sponsored by MorphoSys AG (part of Novartis) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
91
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Multiple Myeloma by Novartis — none open to participants now, none under way, none of them phase 3. Multiple Myeloma · Novartis.

Enrollment
11th of 39
91 · median 43
Started
2011
with 1 other
Phase 1/2
4 of 42
none open now
Registered
21st of 42
by date

Among the 42 studies in Multiple Myeloma by Novartis, this one is the 11th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2011, is one of 4 in phase 1/2, and was the 21st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 42 studies in Multiple Myeloma by Novartis is open now. The open studies under Multiple Myeloma, anywhere →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies in Multiple Myeloma by Novartis as a file.
02

Study summary

This is an open-label, multicentre, dose escalation study to characterize the safety and preliminary efficacy of the human anti-CD38 antibody MOR03087 (MOR202), in adult subjects with relapsed/refractory multiple myeloma, as monotherapy and in adult subjects with relapsed/refractory multiple myeloma in combination with standard therapy.

Read the detailed description

The study enrolled patients aged 18 years or older with relapsed or refractory multiple myeloma and Karnofsky performance status of 60% or higher. Patients were assigned to the different treatment regimens with MOR202 ranging between 0·01 mg/kg and 16 mg/kg in a 3 + 3 design. Dose-escalation and expansion was done either with MOR202 intravenous infusions alone (MOR202 q2w [twice a week] and q1w [weekly] groups) or in combination with dexamethasone (MOR202 with dexamethasone group), with dexamethasone plus pomalidomide (MOR202 with dexamethasone plus pomalidomide group) or plus lenalidomide (MOR202 with dexamethasone plus lenalidomide group). Primary endpoints were safety, MOR202 maximum tolerated dose (or recommended dose) and regimen, and immunogenicity.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • MOR03087 (MOR202)
  • Lenalidomide
  • Pomalidomide
  • CD38
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects 18 years and older
  2. multiple myeloma defined as:

    Parts A, B and C:

    (i) Failure of at least 2 previous therapies which must have included an immunomodulatory agent and a proteasome inhibitor (either together or part of different therapies) (ii) All subjects must have documented progression during or after their last prior therapy for multiple myeloma

    Part D:

    (i) At least 2 previous therapies including lenalidomide and a proteasome inhibitor (ii) All subjects must have documented progression during or within 60 days after their last prior therapy for multiple myeloma

    Part E:

    (i) Received at least one previous therapy (ii) All subjects must have documented progression during or after their last prior therapy for multiple myeloma

  3. Presence of serum M-protein ≥ 0.5 g per 100 mL (≥ 5 g/L) and / or urine M-protein ≥ 200 mg per 24-hour period
  4. (ANC) ≥ 1,000 / mm3
  5. ≥ 8 g/dL
  6. Ability to comply with all study related procedures, medication use and evaluations

Exclusion criteria

Exclusion Criteria:

  1. Primary multiple myeloma
  2. History of significant cerebrovascular disease or sensory or motor neuropathy of toxicity grade 3 or higher
  3. Treatment with systemic agent within 28 days prior to first study treatment
  4. Solitary plasmacytoma or plasma cell leukaemia
  5. Previous allogenic stem cell transplant (SCT)
  6. Prior therapy with other monoclonal antibodies targeting the CD38 antigen or prior therapy with other IgG monoclonal antibodies within 3 months prior to first study treatment, or IgM monoclonal antibodies within 1 month prior to first study treatment
  7. Active systemic infection
  8. Systemic disease preventing study treatment
  9. Multiple myeloma with central nervous system (CNS) involvement
  10. Previous treatment with cytotoxic chemotherapy or large field radiotherapy or other myeloma specific therapy within 28 days prior to first study treatment (radiation to a single site as concurrent therapy is allowed)
  11. Significant uncontrolled cardiovascular disease or cardiac insufficiency ( [NYHA] classes III, IV)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    Phase 1 dose escalation

    Part A: MOR03087 dose escalation; biweekly treatment Part B: MOR03087 dose escalation; weekly treatment Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone For all parts, patients will be treated until disease progression (PD) or until a maximum of 3 years after first treatment.

    Drug: MOR03087 phase 1 dose escalation · Drug: Dexamethasone · Drug: Pomalidomide · Drug: Lenalidomide

  • Experimental
    Phase 2a confirmatory cohorts

    Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone. Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects. Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects. For all parts, patients will be treated until PD or until a maximum of 3 years after first treatment.

    Drug: MOR03087 · Drug: Dexamethasone · Drug: Pomalidomide · Drug: Lenalidomide

Interventions

  • Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle. In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1.

  • MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.

  • Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (\> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.

  • Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.

  • Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087

    1. as monotherapy 2. in combination with dexamethasone 3. in combination with pomalidomide + dexamethasone 4. in combination with lenalidomide + dexamethasone

    Time frame: First cycle of treatment

  2. Number of Participants Who Develop Anti-MOR03087 Antibodies

    Number of participants who develop anti-MOR03087 antibodies, a measure of immunogenicity

    Time frame: during treatment period, maximum 3 years after 1st dose

Secondary outcomes

  1. Overall Response Rate

    number (#) of patients responding (# stringent complete response + # complete response + # very good partial response + # partial response)

    Time frame: maximum 3 years after 1st dose

  2. Time to Progression

    Time to Progression (Kaplan Meier estimate)

    Time frame: patients were observed for up to 36 months

  3. Progression-free Survival

    Progression-free survival (Kaplan Meier estimates)

    Time frame: patients were observed up to 36 months

  4. Duration of Response

    Duration of response (Kaplan Meier estimates)

    Time frame: patients were observed up to 36 months

  5. Pharmacokinetics: Cmax - Maximum Observed Serum Concentration for MOR202

    PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups

    Time frame: up to 7 days after last MOR202 dose

  6. Pharmacokinetics: AUC Cycle 1+2 - Area Under the Time/Concentration Curve for MOR202

    PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups

    Time frame: 56 days

07

Results

Posted Oct 28, 2021

Participant flow

Participant flow — Overall Study
MilestonePart A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + Dexamethasone
Started314182117
Completed314182117
Not completed00000

Outcome measures

PrimaryDetermination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087

1. as monotherapy 2. in combination with dexamethasone 3. in combination with pomalidomide + dexamethasone 4. in combination with lenalidomide + dexamethasone

Time frame:
First cycle of treatment
Reported as:
Number · mg/kg
Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR03087
mg/kgPart A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + Dexamethasone
Determination of Maximum Tolerated Dose and / or Recommended Dose and Dosing Regimen of MOR030871616161616
PrimaryNumber of Participants Who Develop Anti-MOR03087 Antibodies

Number of participants who develop anti-MOR03087 antibodies, a measure of immunogenicity

Time frame:
during treatment period, maximum 3 years after 1st dose
Reported as:
Count of participants · Participants
Number of Participants Who Develop Anti-MOR03087 Antibodies
ParticipantsPart A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + Dexamethasone
Number of Participants Who Develop Anti-MOR03087 Antibodies00000
SecondaryOverall Response Rate

number (#) of patients responding (# stringent complete response + # complete response + # very good partial response + # partial response)

Time frame:
maximum 3 years after 1st dose
Reported as:
Count of participants · Participants
Overall Response Rate
ParticipantsPart A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + Dexamethasone
Overall Response Rate0051011
SecondaryTime to Progression

Time to Progression (Kaplan Meier estimate)

Time frame:
patients were observed for up to 36 months
Reported as:
Median · months
Time to Progression
monthsPart A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + Dexamethasone
Time to Progression1.1 (1.0 to 1.4)2.1 (0.7 to NA)8.4 (1.4 to 11.1)15.9 (4.1 to 25.8)33.2 (5.1 to NA)
SecondaryProgression-free Survival

Progression-free survival (Kaplan Meier estimates)

Time frame:
patients were observed up to 36 months
Reported as:
Median · months
Progression-free Survival
monthsPart A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + Dexamethasone
Progression-free Survival1.1 (1.0 to 1.4)2.1 (0.7 to NA)8.4 (1.4 to 11.1)15.9 (3.0 to 22.1)26.7 (5.1 to NA)
SecondaryDuration of Response

Duration of response (Kaplan Meier estimates)

Time frame:
patients were observed up to 36 months
Reported as:
Median · months
Duration of Response
monthsPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + Dexamethasone
Duration of Response16.7 (1.9 to NA)21.2 (9.2 to NA)32.2 (4.2 to NA)
SecondaryPharmacokinetics: Cmax - Maximum Observed Serum Concentration for MOR202

PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups

Time frame:
up to 7 days after last MOR202 dose
Reported as:
Mean · µg/mL
Pharmacokinetics: Cmax - Maximum Observed Serum Concentration for MOR202
µg/mL4 mg/kg QW8 mg/kg QW16 mg/kg QW
Pharmacokinetics: Cmax - Maximum Observed Serum Concentration for MOR202137.86 ± 79.43311.67 ± 118.33681.53 ± 226.69
SecondaryPharmacokinetics: AUC Cycle 1+2 - Area Under the Time/Concentration Curve for MOR202

PK analysis for MOR202 4, 8 and 16 mg/kg IV once weekly dose groups only, since serum concentrations of MOR202 were substantially affected by target mediated drug disposition effects for remaining dose groups

Time frame:
56 days
Reported as:
Mean · mg*days/L
Pharmacokinetics: AUC Cycle 1+2 - Area Under the Time/Concentration Curve for MOR202
mg*days/L4 mg/kg QW8 mg/kg QW16 mg/kg QW
Pharmacokinetics: AUC Cycle 1+2 - Area Under the Time/Concentration Curve for MOR2023307.57 ± 2332.077970.15 ± 4289.2118178.57 ± 8414.44

Adverse events

Collected over during the entire period of trial drug application and beyond until end of study visit/up to 30 days after last administration of study drug. Patients stayed on study drug up to 3 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: MOR03087 Biweekly Dose Escalation2/31 (6.5%)13/31 (41.9%)31/31 (100%)
Part B: MOR03087 Weekly Dose Escalation0/4 (0%)4/4 (100%)4/4 (100%)
Part C: MOR03087 Plus Dexamethasone0/18 (0%)7/18 (38.9%)18/18 (100%)
Part D: MOR03087 Plus Pomalidomide + Dexamethasone1/21 (4.8%)20/21 (95.2%)21/21 (100%)
Part E: MOR03087 Plus Lenalidomide + Dexamethasone4/17 (23.5%)14/17 (82.4%)17/17 (100%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventPart A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + Dexamethasone
Infusion-related reactionInjury, poisoning and procedural complications4/314/40/181/210/17
PneumoniaInfections and infestations1/310/41/186/211/17
ThrombocytopeniaBlood and lymphatic system disorders0/311/40/181/210/17
Atrial FibrillationCardiac disorders0/311/40/181/210/17
PericarditisCardiac disorders0/311/40/180/210/17
InfectionInfections and infestations0/311/40/180/210/17
Respiratory tract infectionInfections and infestations0/310/40/183/210/17
Plasma Cell MyelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/310/40/180/210/17
BronchitisInfections and infestations0/310/42/180/210/17
PyrexiaGeneral disorders0/310/41/182/210/17
Most frequent other events
Showing 10 of 135
Most frequent other events
EventPart A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + Dexamethasone
LeukopeniaBlood and lymphatic system disorders8/314/48/1817/2115/17
NeutropeniaBlood and lymphatic system disorders4/313/48/1819/2112/17
LymphopeniaBlood and lymphatic system disorders5/312/48/1814/2113/17
ThrombocytopeniaBlood and lymphatic system disorders3/311/46/1814/2111/17
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)16/312/412/189/213/17
ConstipationGastrointestinal disorders4/310/40/185/2111/17
DiarrheaGastrointestinal disorders7/311/44/1811/2110/17
FatigueGeneral disorders11/310/46/1812/216/17
Muscle spasmMusculoskeletal and connective tissue disorders3/310/42/185/219/17
AnaemiaBlood and lymphatic system disorders13/311/47/1811/216/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + DexamethasoneTotal
<=18 years000000
Between 18 and 65 years81710834
>=65 years2331111957
Sex: Female, Male
Sex: Female, Male(Participants)Part A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + DexamethasoneTotal
Female12088533
Male19410131258
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + DexamethasoneTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White31418211791
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Part A: MOR03087 Biweekly Dose EscalationPart B: MOR03087 Weekly Dose EscalationPart C: MOR03087 Plus DexamethasonePart D: MOR03087 Plus Pomalidomide + DexamethasonePart E: MOR03087 Plus Lenalidomide + DexamethasoneTotal
Austria003104
Germany31415201787
08

Study locations

10 sites
  • AKH (Allgemeines Krankenhaus der Stadt Wien), Abteilung für Klinische Onkologie, Universitätsklinik für Innere Medizin I
    Vienna, 1090, Austria
  • Charité - Universitätsmedizin Berlin, CBF: Campus Benjamin Franklin, CC 14: Tumormedizin, Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie
    Berlin, 12200, Germany
  • Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Medizinische Klinik 5 - Hämatologie und Internist. Onkologie, Universitätsklinikum Erlangen
    Erlangen, 91054, Germany
  • Medizinische Universitätsklinik, Abt. Innere Medizin I
    Freiburg, 79106, Germany
  • Universitäsklinikum Heidelberg, Klin.-Pharmakologisches Studienzentrum
    Heidelberg, 69120, Germany
  • Sektion für Stammzell- und Immuntherapie, II. Medizinischen Klinik,
    Kiel, 24105, Germany
  • Klinikum rechts der Isar/ Studien / III. Med. Klinik
    Munich, 81675, Germany
  • Medizinische Klinik II, Abt. Hämatologie, Onkologie,
    Tübingen, 7206, Germany
  • Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Studienambulanz für Hämatologie/Onkologie und Infektiologie
    Würzburg, 97080, Germany
09

References and documents

Publications

  • Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, Ferstl B, Schub N, Rollig C, Weisel K, Winderlich M, Griese J, Hartle S, Weirather J, Jarutat T, Peschel C, Chatterjee M. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 2020 May;7(5):e381-e394. doi: 10.1016/S2352-3026(19)30249-2. Epub 2020 Mar 11. PubMed 32171061 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in Aug 2020, 109 months.

Results were first posted in Oct 2021, 1 year 2 months after primary completion.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's 109 months is above that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2011
First posted
Aug 22, 2011
StartActual
Jul 2011
Primary completionActual
Aug 2020
CompletionActual
Aug 2020
Results first posted
Oct 28, 2021
Last update
Nov 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01421186
Lead sponsor
MorphoSys AG
Responsible party
Sponsor
First posted
Aug 22, 2011
Start date
Jul 2011
Primary completion
Aug 2020
Completion
Aug 2020
Results posted
Oct 28, 2021
Last update
Nov 16, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Felzartamab

Start the discussion